
PMC:7408073 / 66250-66472
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T409 | 157-167 | Body_part | denotes | neutrophil | http://purl.org/sig/ont/fma/fma62860 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2329 | 66-73 | Species | denotes | patient | Tax:9606 |
2332 | 29-34 | Chemical | denotes | metal | MESH:D008670 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T820 | 3-4 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T821 | 107-112 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T92153 | 35-51 | Chemical | denotes | chelating agents | http://purl.obolibrary.org/obo/CHEBI_38161 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T319 | 0-222 | Sentence | denotes | As a result, treatments with metal chelating agents require close patient monitoring, including laboratory tests of renal and hepatic function, and absolute neutrophil count should be monitored before and during treatment. |